Citation Impact
Citing Papers
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Targeting natural killer cells and natural killer T cells in cancer
2012
NK cells for cancer immunotherapy
2020
Gene editing for immune cell therapies
2019
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
2017
Nocardiosis: Updated Clinical Review and Experience at a Tertiary Center
2010 Standout
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
2021 StandoutNobel
Engineering Natural Killer Cells for Cancer Immunotherapy
2017
Natural killer cells and other innate lymphoid cells in cancer
2018
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
2017
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
2015
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
2015
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
2013 StandoutNobel
Systemic amyloidosis
2015 Standout
mRNA transcript therapy
2014 StandoutNobel
The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
2017
NK cells and cancer: you can teach innate cells new tricks
2015
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
2016
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
2022 StandoutNobel
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
2018
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma
2017
Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems
2018 Standout
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
2014
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
2014
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Strategies for Combining Immunotherapy with Radiation for Anticancer Therapy
2015 StandoutNobel
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
2016
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Works of D.M. Benson being referenced
Pulmonary Nocardia and Aspergillus co‐infection in a patient with chronic graft‐versus‐host disease
2007
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma
2007
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
2013
Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis
2011
A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma.
2010